LeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
LeMaitre Vascular (LMAT) has scheduled its Q4 2024 earnings release for Thursday, February 27, 2025, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LeMaitre Vascular (LMAT) has scheduled its Q4 2024 earnings release for Thursday, February 27, 2025, after market close. The company will host a conference call at 5:00 PM EST on the same day to discuss financial results, business highlights, and company outlook. Interested parties can access the live call by registering online, and all registrants will receive dial-in information and a PIN. Additionally, an audio webcast will be available live and for replay through the company's investor relations website.
Details
News Market Reaction – LMAT
The recorded move for LMAT in the trading session of this news was +2.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURLINGTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its fourth quarter 2024 financial results on Thursday, February 27, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay through a webcast at www.lemaitre.com/investor.
About LeMaitre
LeMaitre is a provider of devices, implants, and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Additional information can be found at www.lemaitre.com.
LeMaitre and the LeMaitre logo are registered trademarks of LeMaitre Vascular, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.